更新于：2024-05-01

Pemphigus, Benign Familial

良性家族性天疱疮

更新于：2024-05-01

基本信息

别名

BCPM、BENIGN CHRONIC PEMPHIGUS、Benign Chronic Pemphigus

+ [46]

简介

An autosomal dominantly inherited skin disorder characterized by recurrent eruptions of vesicles and BULLAE mainly on the neck, axillae, and groin. Mutations in the ATP2C1 gene (encoding the secretory pathway Ca2++/Mn2++ ATPase 1 (SPCA1)) cause this disease. It is clinically and histologically similar to DARIER DISEASE - both have abnormal, unstable DESMOSOMES between KERATINOCYTES and defective CALCIUM-TRANSPORTING ATPASES. It is unrelated to PEMPHIGUS VULGARIS though it closely resembles that disease.

关联

项与良性家族性天疱疮相关的药物

Betamethasone Dipropionate

倍他米松二丙酸酯

靶点

作用机制

GR激动剂

在研机构

Shionogi & Co., Ltd. [+3]

原研机构

Shionogi & Co., Ltd.

在研适应症

斑块状银屑病 [+18]

非在研适应症

嗜皮菌病

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1975-01-29

项与良性家族性天疱疮相关的临床试验

NCT05007223 / CompletedN/A

Characterization and Analysis of the Skin Microbiome in Hailey-Hailey Disease

Hailey-Hailey disease is an autosomal dominant disorder caused by a genetic defect in a calcium ATPase (ATP2C1) leading to a defect in keratinocyte adhesion. The characteristic of this disease is the involvement of intertriginous areas of the skin, which are the moist sites including the axillary vault and the inguinal crease. The composition of microbial communities is primarily dependent on the physiology of the skin site and the moist sites have distinct compositions of skin microorganisms. In addition, treatment with doxycycline is often helpful in the management of Hailey-Hailey disease. These findings suggest a role of the skin microbiome in the pathogenesis of Hailey-Hailey disease.
The purpose of this study is to characterize the skin microbiome in patients with Hailey-Hailey disease by the 16S method, to better understand the pathogenesis of the disease and to discover new therapeutic targets in the future.

开始日期2020-05-08

申办/合作机构

Gangnam Severance Hospital

NCT03849989 / CompletedN/A

Expression of hSPCA1 and Ultrastructural Analysis of the Skin Before and After Laser Therapy in Hailey-Hailey Disease

Hailey-Hailey disease is a genetic acantholytic dermatosis characterized by continuous erosion of the skin that results in a burning, painful sensation and restricts the patient in daily life. This disorder results from a genetic defect in a calcium pump, i.e. the hSPCA1 pump. Calcium pumps are crucial for the processing of cell-cell adhesion proteins such as E-cadherin, part of desmosomes, the major glue between keratinocytes in skin epidermis. Today therapy is mainly focussed on symptom relief and prevention of secondary infection.
Ablative laser therapy is known to result in a speedy healing of the affected skin site within 2 weeks following laser therapy. The fact that the treated skin site remains clear from this acantholytic disorder in the months/years following ablation, regardless the existence of a germline mutation, suggests that an epigenetic modification occurs in the process of wound healing.
Objective: to (1) study the expression of hSPCA1 in keratinocytes before and after laser therapy and (2) verify the loss of acantholysis by immunohistochemistry and electron microscopy of cell-cell adhesions before and after laser therapy

开始日期2018-12-21

申办/合作机构

Maastricht University Medical Center

NCT03271385 / CompletedN/A

EARLY Differentiation of MYOcardial Hypertrophy Between Hypertensive Heart Disease and Hypertrophic Cardiomyopathy

Differentiating hypertrophic cardiomyopathy (HCM) from hypertensive heart disease (HHD) unavoidably encounters diagnostic challenges especially in patient of suspected HCM with history of hypertension. Diverse and overlapping forms of HCM can often lead to ambiguity when diagnosis is based on a single genetic or morphological index.
The investigators have deduced a integrated formula based on cardiac magnetic resonance (CMR) imaging and established a differentiating flow-chart between HCM and HHD, the investigators aim to identify their method in the current multi-center trial.

开始日期2017-07-01

申办/合作机构

上海仁玑医院管理有限公司

[+6]

100 项与良性家族性天疱疮相关的临床结果

登录后查看更多信息

100 项与良性家族性天疱疮相关的转化医学

登录后查看更多信息

0 项与良性家族性天疱疮相关的专利（医药）

登录后查看更多信息

1,431

项与良性家族性天疱疮相关的文献（医药）

2024-02-01·Kidney360

Cardiovascular Outcomes in Home Hemodialysis and Peritoneal Dialysis Patients.

Article

作者: Silvi Shah ; Eric Weinhandl ; Nupur Gupta ; Anthony C Leonard ; Annette L Christianson ; Charuhas V Thakar

BACKGROUND:

Cardiovascular disease is the leading cause of morbidity and mortality in patients with end-stage kidney disease. Little is known about differences in cardiovascular outcomes between home hemodialysis (HHD) and peritoneal dialysis (PD).

METHODS:

We evaluated 68,645 patients who initiated home dialysis between 1/1/2005 and 12/31/2018 using the United States Renal Data System with linked Medicare claims. Rates for incident cardiovascular events of acute coronary syndrome, heart failure, and stroke hospitalizations were determined. Using adjusted time-to-event models, the associations of type of home dialysis modality with the outcomes of incident cardiovascular events, cardiovascular death, and all-cause death were examined.

RESULTS:

The mean age of patients in the study cohort was 64±15 years, and 42.3% were women. Mean time of follow up was 1.8±1.6 years. The unadjusted cardiovascular event rate was 95.1 per thousand person-years [PTPY] (95% CI, 93.6-96.8), with a higher rate in patients on HHD than on PD (127.8 PTPY; 95% CI, 118.9-137.2 vs. 93.3 PTPY; 95% CI, 91.5-95.1). However, HHD was associated with a slightly lower adjusted risk of cardiovascular events than PD (HR, 0.92; 95% CI, 0.85 to 0.997). Compared to PD patients, HHD patients had 42% lower adjusted risk of stroke (HR, 0.58; 95% CI, 0.48-0.71), 17% lower adjusted risk of acute coronary syndrome (HR, 0.83; 95% CI, 0.72-0.95), and no difference in risk of heart failure (HR, 1.05; 95% CI, 0.94-1.16). HHD was associated with 22% lower adjusted risk of cardiovascular death (HR, 0.78; 95% CI, 0.71-0.86) and 8% lower adjusted risk of all-cause death (HR, 0.92; 95% CI, 0.87-0.97) as compared to PD.

CONCLUSION:

Relative to PD, HHD is associated with decreased risk of stroke, acute coronary syndrome, cardiovascular death, and all-cause death. Further studies are needed to better understand the factors associated with differences in cardiovascular outcomes by type of home dialysis modality in patients with kidney failure.

2024-01-23·Nutrients

Diet-Induced Severe Hyperhomocysteinemia Promotes Atherosclerosis Progression and Dysregulates the Plasma Metabolome in Apolipoprotein-E-Deficient Mice.

Article

作者: Stephen G Andrews ; Anthony M Koehle ; Devendra Paudel ; Thomas Neuberger ; A Catharine Ross ; Vishal Singh ; Teodoro Bottiglieri ; Rita Castro

Atherosclerosis and resulting cardiovascular disease are the leading causes of death in the US. Hyperhomocysteinemia (HHcy), or the accumulation of the intermediate amino acid homocysteine, is an independent risk factor for atherosclerosis, but the intricate biological processes mediating this effect remain elusive. Several factors regulate homocysteine levels, including the activity of several enzymes and adequate levels of their coenzymes, including pyridoxal phosphate (vitamin B6), folate (vitamin B9), and methylcobalamin (vitamin B12). To better understand the biological influence of HHcy on the development and progression of atherosclerosis, apolipoprotein-E-deficient (apoE^-/- mice), a model for human atherosclerosis, were fed a hyperhomocysteinemic diet (low in methyl donors and B vitamins) (HHD) or a control diet (CD). After eight weeks, the plasma, aorta, and liver were collected to quantify methylation metabolites, while plasma was also used for a broad targeted metabolomic analysis. Aortic plaque burden in the brachiocephalic artery (BCA) was quantified via 14T magnetic resonance imaging (MRI). A severe accumulation of plasma and hepatic homocysteine and an increased BCA plaque burden were observed, thus confirming the atherogenic effect of the HHD. Moreover, a decreased methylation capacity in the plasma and aorta, indirectly assessed by the ratio of S-adenosylmethionine to S-adenosylhomocysteine (SAM:SAH) was detected in HHD mice together with a 172-fold increase in aortic cystathionine levels, indicating increased flux through the transsulfuration pathway. Betaine and its metabolic precursor, choline, were significantly decreased in the livers of HHD mice versus CD mice. Widespread changes in the plasma metabolome of HHD mice versus CD animals were detected, including alterations in acylcarnitines, amino acids, bile acids, ceramides, sphingomyelins, triacylglycerol levels, and several indicators of dysfunctional lipid metabolism. This study confirms the relevance of severe HHcy in the progression of vascular plaque and suggests novel metabolic pathways implicated in the pathophysiology of atherosclerosis.

2024-01-16·Journal of clinical medicine

Hypertensive Heart Disease: A Narrative Review Series-Part 3: Vasculature, Biomarkers and the Matrix of Hypertensive Heart Disease.

Review

作者: Valeriya Nemtsova ; Annina S Vischer ; Thilo Burkard

Over the last few decades, research efforts have resulted in major advances in our understanding of the pathophysiology of hypertensive heart disease (HHD). This is the third part of a three-part review series. Here, we focus on the influence of high blood pressure on the micro- and macroalterations that occur in the vasculature in HHD. We also provide an overview of circulating cardiac biomarkers that may prove useful for a better understanding of the pathophysiology, development and progression of HHD, and may play a unique role in the diagnostic and prognostic evaluation of patients with HHD, taking into account their properties showing as abnormal long before the onset of the disease. In the conclusion, we propose an updated definition of HHD and a matrix for clinical classification, which we suspect will be useful in practice, allowing an individual approach to HHD patients.

项与良性家族性天疱疮相关的新闻（医药）

2023-11-10

·美通社

费森尤斯医疗"森态圈"智慧"绿色"生态系统亮相进博会

上海2023年11月10日 /美通社/ -- 第六届中国国际进口博览会上全球知名的血液净化医疗产品与服务企业费森尤斯医疗，携旗下智慧"绿色"生态系统"森态圈"隆重亮相。第六次中国慢性病及危险因素监测结果显示 [1] ，目前估计我国8200万成年人有慢性肾脏病（CKD），截至2022年底，中国透析患者例数已达到984,809人，新增177,445人 [2] 。日益增长的治疗需求对比透析中心与ICU医护人员辛劳负荷运作的现状，加上透析中心与ICU对管理、合规性、日程安排、再教育等方面的要求持续增长，如何为透析与ICU医护人员"减负"、如何为中心"增效"成为血液净化治疗未来可持续发展的关键。针对这关键需求，费森尤斯医疗推出智慧"绿色"生态系统"森态圈"。借鉴生物生态系统的整体性和发展性，并重点构建整合更高效性能的医疗生态服务闭环系统，强调通过产品联动、硬件与软件联动、医护与患者联动，从流程和效率上赋能医护、优化减低整体医疗成本、打造价值医疗新引擎。 "森态圈"系统包括两个方面：硬件层面，从在院透析到居家透析，再到重症多器官支持，为血液净化提供了一套绿色治疗生态体系。具体举例，针对先进血液透析解决方案，包含：6008CAREsystem血液透析滤过一体化设备， Fx CorDiax 透析器，保障透析用水质量的全能数字型水处理设备AquaA、全密闭集中供液系统 Granumix等设备；软件与服务层面，以端到端数据驱动为核心，通过自有数字化解决方案TDMS+ 智慧系统，基于物联网等技术和专业服务，在临床上实现协助医护端到端"智能化"管理与分析：提质增效、优化减低整体医疗成本。为应对中国的三级医疗服务体系的需求，费森尤斯医疗细化了针对不同层级体系的"森态圈"系统，提供广泛的产品组合用以满足不同层级医疗机构的差异化需求。据统计，由现代透析设备、水处理系统和数字技术的"森"态组合在血液透析日常工作流程中使用，经过费森尤斯医疗全球经验实践得出：有85个步骤得到净改善，流程效率提高了49%-58%不等 [3] 。覆盖疾病管理全病程费森尤斯医疗自进入中国市场以来，不仅把国际上先进的血液净化疗法理念引入中国，并且在逐步深入地了解中国患者的实际治疗需求后，先后推出了合适满足中国不同层级医疗机构的血液净化技术。例如4008A是一款自研发初期就包含到满足中国基层患者透析需求而生的中国本土设备，而5008S可以为患者实现较高智能化的血液透析滤过疗法和居家血液透析（HHD）治疗。费森尤斯医疗的新一代创新产品也满足了危重病护理和居家透析治疗领域的需求。重症"双子星"— 全新一代CRRT平台multiFiltrate PRO和长效灵动ECMO设备XENIOS森诺时，通过体外膜肺氧合疗法（ECMO）联合连续性肾脏替代治疗（CRRT）疗法，为中国危重症患者提供坚实的多器官支持。在居家透析治疗领域，费森尤斯医疗还展示了 s leep · safe harmony 新一代自动腹膜透析机和 stay · safe® balance 中性腹膜透析液，使临床具有更多个性化治疗模式的选择。 "森"耕中国市场，在中国●为中国中国是费森尤斯医疗最重要的全球化市场之一，费森尤斯医疗已在中国为患者和医疗机构提供服务超过20余载，并不断开拓服务边界。直至今日，费森尤斯医疗已在上海建立了独立的研发中心，并在江苏省常熟建立了自己的生产基地，这些项目使得产品的设计、开发和生产能够满足中国患者的需求——包括4008A服务本土的透析设备，全包裹式服务本土与 Biofine ® 环保材质腹膜透析液袋与附件等。 2021年，国务院办公厅印发了《关于推动公立医院高质量发展的意见》，要求公立医院必须把发展的着力点放在提升质量和效率上，要更加注重内涵发展、技术发展、能力水平发展、服务质量发展，提高发展的"含金量"。费森尤斯医疗此次打造的"森态圈"是响应政策的号召、顺应时代所需的重要创举。对此，费森尤斯医疗中国区总裁陈玉刚先生表示：费森尤斯医疗深耕中国市场数十年来，不断加强在中国的投资和研发与生产力度，希望能够借助智慧"绿色"生态系统"森态圈"打造出一套创新的解决方案，帮助医护提质增效；同时，也能够为不同治疗需求的患者带去多种疗法选择，助力实现健康中国2030。关于费森尤斯医疗费森尤斯医疗是全球知名的血液净化产品和医疗服务的供应商。全球约有390万肾脏疾病患者定期接受透析治疗。费森尤斯医疗在世界各地拥有4,014家透析诊所中心，为全球约342,000名肾友提供透析治疗。费森尤斯医疗也是透析产品（例如透析机或透析器）的领先供应商。一体化肾脏护理解决方案是我们的核心业务，除此之外，费森尤斯医疗还专注于肾脏相关领域和重症领域的拓展。费森尤斯医疗目前已在法兰克福证券交易所(FME)和纽约证券交易所(FMS)上市。更多信息，请访问公司网站： www.freseniusmedicalcare. cn 免责声明本文发布的所有信息和内容仅供一般信息用途，由费森尤斯医疗保健集团公司提供，不作任何明示或暗示的保证或陈述，包括但不限于其准确性、完整性或正确性。本公告中提到的产品或服务的可获得性取决于各国的监管要求和产品或服务注册状况，产品和技术规格可能会在不另行通知的情况下发生变化。详情请联系费森尤斯医疗相关代表。本新闻稿包含了各种风险和不确定性的前瞻性情况评估或说明。实际结果可能由于受到各种不确定因素的影响而完全不同，这些不确定因素包括并不限于，业务变化、经济和竞争环境的影响、法律条款的修改、监管机构的获准、因新型冠状病毒肺炎（COVID-19）所产生的临床研究结果、外汇汇率的波动、诉讼或调查程序中的不确定性以及融资等。费森尤斯医药用品（上海）有限公司将不因本新闻稿中所提到的任何前瞻性情况评估或说明而承担相关责任。 [1] Prevalence of Chronic Kidney Disease in China Results From the Sixth China Chronic Disease and Risk Factor Surveillance：https:\/\/pubmed.ncbi.nlm.nih.gov\/36804760\/ [2] 摘自CNA2023 中国医师协会肾脏内科医师分会2023年学术年会大会主题报告内容 [3] 数据来源：费森尤斯医疗内部流程步骤分析（存档的未发表数据）

2023-09-19

·PRNewswire

Quanta Announces FDA 510(k) Submission for Home Use of Quanta Dialysis System

New expanded indication will increase home hemodialysis device options available to patients with end-stage kidney disease BEVERLY, Mass., Sept. 19, 2023 /PRNewswire/ -- Quanta Dialysis Technologies®, a medical technology company committed to making kidney care more accessible, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for indication expansion of the Quanta™ Dialysis System, a compact and easy-to-use hemodialysis device. The Quanta Dialysis System is currently indicated for use in chronic and acute care settings. The new submission seeks to expand use to include self-care, in-home hemodialysis. Continue Reading A new FDA 510(k) was submitted for indication expansion of the Quanta Dialysis System for self-care, in-home hemodialysis. The pending FDA clearance will increase the number of home hemodialysis device options available to patients with end-stage kidney disease. According to the U.S. Renal Data System, there are over 490,000 people in the U.S. who use hemodialysis to treat their end-stage kidney disease (ESKD). Home hemodialysis (HHD), which replaces the thrice-weekly commute to a dialysis clinic to receive treatment, accounts for 2% of the total hemodialysis population.i Studies suggest that HHD has many benefits over traditional in-center dialysis such as improvements to quality of life, health outcomes and access to care. In response to the benefits of HHD, the Centers for Medicare and Medicaid Services (CMS) established a program to encourage greater use of home dialysis and kidney transplants for Medicare beneficiaries.ii "The FDA submission for in-home use of the Quanta Dialysis System represents a significant milestone for Quanta in our journey to make dialysis more accessible to every patient in every setting," said Alejandro Galindo, Quanta Chief Executive Officer. "The Quanta Dialysis System is already providing patients in the U.K. with the freedom and flexibility that HHD offers. With clearance of this 510(k), patients in the U.S. will have more control over their care, and choice in where, when and how they receive treatment." This submission, pending regulatory clearance from the FDA, would make the Quanta Dialysis System the third device in the United States indicated for HHD in patients with end-stage kidney disease (ESKD). FDA clearance for the expanded indication is expected in 2024. Quanta's 510(k) submission is supported by clinical data from its Home Run™ study, a prospective, multi-center, open-label trial to assess the efficacy and safety of the Quanta Dialysis System for HHD. Full results from the study will be shared this November during a poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week in Philadelphia, Pennsylvania. About End-Stage Kidney Disease End-stage kidney disease is the final stage of chronic kidney disease, where kidney function has declined enough to the point where the kidneys can no longer function on their own. With fully functioning kidneys, waste and excess fluids from the blood are filtered and then excreted in urine. For those with ESKD, the kidneys lose their filtering abilities and dangerous levels of fluid, electrolytes and waste build up in the body. Approximately 800,000 people in the United States are living with ESKD, 71% of which rely on dialysis to manage the disease, while the remaining 29% have a functioning kidney transplant. About Quanta Dialysis Technologies Quanta Dialysis Technologies is committed to making dialysis accessible to every patient in every setting with its Quanta Dialysis System. As a portable device with performance comparable to larger, traditional machines, the Quanta Dialysis System is a modular and powerful solution that provides the clinical versatility needed to deliver dialysis care across multiple settings. With a simple-to-use and intuitive user interface, it is designed to be operated by a broad range of users to bring dialysis directly to patients. The Quanta Dialysis System is commercially available in the United Kingdom for home and hospital use. In the United States, it is FDA-cleared (K222067) for use in chronic and acute care settings, with treatment types including intermittent hemodialysis (IHD), sustained low efficiency dialysis (SLED), prolonged intermittent renal replacement therapy (PIRRT), slow continuous ultrafiltration (SCUF), and continuous venovenous hemodialysis (CVVHD). To learn more about Quanta and its products, visit quantadt.com. Media Contact: Melinda Freson [email protected] i United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022. ii Centers for Medicare and Medicade Services. ESRD Treatment Choices (ETC) Model. SOURCE Quanta Dialysis Technologies

2023-08-23

·PRNewswire

Fresenius Medical Care Announces FDA Clearance of Versi®HD with GuideMe Software

WALTHAM, Mass., Aug. 23, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for Versi®HD with GuideMe Software, a completely reinvented self-guided interface for the company's VersiHD chronic home hemodialysis (HHD) system. VersiHD with GuideMe Software aims to transform the experience of HHD for patients and nurses. Continue Reading As the established leader in HHD, NxStage from Fresenius Medical Care, draws on its experience of over 30 million patient treatments at home over nearly two decades, serving patients in more than 45,000 homes with a broad diversity of water sources across the U.S. VersiHD with GuideMe Software provides graphical walk-through guidance that aims to enhance ease of use and confidence for both patients and nurses. It is designed to improve patient training time, ease the transition to home, and make the training experience easier for new users. "With over 13,000 HHD patients in the U.S. alone, we are excited to amplify the innovation NxStage offers with advanced technologies, like VersiHD with GuideMe Software," said Dr. Katarzyna Mazur-Hofsäß, CEO of Fresenius Medical Care's Care Enablement segment. "We are committed to providing cutting-edge solutions to improve the health and well-being of dialysis patients by challenging the standard of home dialysis with the design of industry-leading products." "We expect VersiHD with GuideMe Software to further simplify home hemodialysis for patients during training and at home," said Dr. Brigitte Schiller, Senior Vice President, Medical Officer, Home Therapies at Fresenius Medical Care. "As a result of this software upgrade, patients and their care partners will have additional support to be confident with the therapy at home. VersiHD with GuideMe Software will support Fresenius Medical Care's mission of advancing access to home therapies to more patients." NxStage has had many significant innovations over the years guided by patient input starting with the first portable HHD machine, NxStage System One™, in 2005 followed by the introduction of the PureFlow™ DI Water Purification System in 2006. Nx2me Connected Health®, the first Connected Health platform for HHD followed in 2014. The NxStage System One was the first machine to receive FDA clearance for Nocturnal HHD indication in 2014 and also the first to receive FDA clearance for Solo HHD indication in 2017. In 2017, NxStage introduced the VersiHD touchscreen cycler. Over 95% of HHD patients in the U.S. use the NxStage HHD system. VersiHD with GuideMe Software will initially be available in selected markets in 2023. Existing VersiHD systems will be upgradeable to GuideMe Software. For more information about VersiHD with GuideMe Software, please visit Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed. © 2023 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, NxStage, the triangle logo, VersiHD, PureFlow and Nx2me are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners. Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,050 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS). For more information visit the Company's website at . Disclaimer: This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release. Media Contact Leif Heussen T +49 6172 608-4030 [email protected] Emanuela Cariolagian T +1 800 723-2384 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com SOURCE Fresenius Medical Care Holdings, Inc.